
Sign up to save your podcasts
Or


In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
We also cover
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.
By Sasha High4.9
3434 ratings
In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
We also cover
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.

579 Listeners

2,113 Listeners

336 Listeners

612 Listeners

49 Listeners

1,667 Listeners

417 Listeners

257 Listeners

217 Listeners

12 Listeners

361 Listeners

35 Listeners

167 Listeners

17 Listeners

38 Listeners